HUP0402025A2 - Új benzofenon származékok és sóik és alkalmazásuk - Google Patents

Új benzofenon származékok és sóik és alkalmazásuk

Info

Publication number
HUP0402025A2
HUP0402025A2 HU0402025A HUP0402025A HUP0402025A2 HU P0402025 A2 HUP0402025 A2 HU P0402025A2 HU 0402025 A HU0402025 A HU 0402025A HU P0402025 A HUP0402025 A HU P0402025A HU P0402025 A2 HUP0402025 A2 HU P0402025A2
Authority
HU
Hungary
Prior art keywords
group
arthritis
general formula
optionally substituted
bensophenone
Prior art date
Application number
HU0402025A
Other languages
English (en)
Inventor
Hisaaki Chaki
Hironori Kotsubo
Tadashi Tanaka
Yukihiko Aikawa
Shuichi Hirono
Shunichi Shiozawa
Original Assignee
Toyama Chemical Co., Ltd.
Shuichi Hirono
Shunichi Shiozawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd., Shuichi Hirono, Shunichi Shiozawa filed Critical Toyama Chemical Co., Ltd.
Publication of HUP0402025A2 publication Critical patent/HUP0402025A2/hu
Publication of HUP0402025A3 publication Critical patent/HUP0402025A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/34—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/76—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/34—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/88—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

A találmány tárgya (1) általános képletű benzofenonszármazék vagysója, ahol az általános képletben R1 jelentése például adott esetbenhelyettesített heterociklusos csoport vagy helyettesítettfenilcsoport; Z jelentése például alkiléncsoport; R2 jelentése példáuladott esetben alkilcsoporttal védett karboxilcsoport; R3 jelentésepéldául adott esetben védett hidroxilcsoport; R4 jelentése példáuladott esetben helyettesített cikloalkoxicsoport; és R5 jelentésepéldául hidrogénatom. Az említett származék ízületi gyulladás ellenihatással rendelkezik, gátolja az izületi gyulladás okoztacsontpusztulást, nagy biztonsággal alkalmazható és in vivo kiválófarmakokinetikai viselkedést mutat, ezért terápiás hatóanyagkéntalkalmazható az izületi gyulladás kezelésére. Ezek a vegyületekgátolják az AP-1 működését, ezáltal felhasználhatók a túlzott AP-1expresszióval kapcsolatos betegségek megelőzésére vagy kezelésére. Ó
HU0402025A 2001-11-16 2002-11-13 Novel bensophenone derivatives or salts thereof and their use HUP0402025A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001351217 2001-11-16
JP2002209382 2002-07-18
PCT/JP2002/011846 WO2003042150A1 (fr) 2001-11-16 2002-11-13 Nouveaux derives de benzophenone ou sels de ceux-ci

Publications (2)

Publication Number Publication Date
HUP0402025A2 true HUP0402025A2 (hu) 2005-02-28
HUP0402025A3 HUP0402025A3 (en) 2006-01-30

Family

ID=26624559

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402025A HUP0402025A3 (en) 2001-11-16 2002-11-13 Novel bensophenone derivatives or salts thereof and their use

Country Status (21)

Country Link
US (1) US7772285B2 (hu)
EP (1) EP1445249B1 (hu)
JP (1) JP4554926B2 (hu)
KR (1) KR100947253B1 (hu)
CN (1) CN1602291B (hu)
AU (1) AU2002349777B2 (hu)
BR (1) BR0214177A (hu)
CA (1) CA2467261C (hu)
CY (1) CY1113657T1 (hu)
DK (1) DK1445249T3 (hu)
ES (1) ES2394963T3 (hu)
HU (1) HUP0402025A3 (hu)
IL (2) IL161736A0 (hu)
MX (1) MXPA04004654A (hu)
NO (1) NO329094B1 (hu)
NZ (1) NZ532810A (hu)
PL (1) PL206100B1 (hu)
PT (1) PT1445249E (hu)
RO (1) RO123430B1 (hu)
WO (1) WO2003042150A1 (hu)
ZA (1) ZA200403373B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615538B2 (en) * 1993-10-29 2009-11-10 Shunichi Shiozawa Method for therapy of rheumatoid arthritis
JP4853759B2 (ja) * 2004-05-27 2012-01-11 日本農薬株式会社 置換ピラジンカルボン酸アニリド誘導体又はその塩類、その中間体及び農園芸用薬剤並びにその使用方法
TWI355380B (en) * 2004-05-27 2012-01-01 Nihon Nohyaku Co Ltd Substituted pyrazinecarboxanilide derivatives or s
US8329694B2 (en) 2005-06-24 2012-12-11 Toyama Chemical Co., Ltd. Quinoxalinones as antibacterial composition
AU2012200254B2 (en) * 2006-02-21 2012-08-30 Toyama Chemical Co., Ltd. Process for the production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro- 1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process
CN101389614B (zh) * 2006-02-21 2012-10-31 富山化学工业株式会社 3-[5-[4-(环戊氧基)-2-羟基苯甲酰基]-2-[(3-氧代-2-取代的-2,3-二氢-1,2-苯并异*唑-6-基)甲氧基]苯基]丙酸酯的制备方法和用于该方法的中间体
NZ593062A (en) * 2006-02-21 2012-04-27 Toyama Chemical Co Ltd Process for production of 3-[5-[4-cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process
PT2022788E (pt) * 2006-05-26 2010-10-04 Toyama Chemical Co Ltd Novo cristal de ácido 3-[5-[4-(ciclopentiloxi)-2- hidroxibenzoíl]-2-[(3-hidroxi-1,2-benzisoxazol-6- il)metoxi]fenil]propiónico
DK2022497T3 (da) * 2006-05-26 2014-05-19 Toyama Chemical Co Ltd Oral sammensætning, omfattende 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxyphenylpropionsyre eller salt deraf
WO2008012371A1 (en) * 2006-07-28 2008-01-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of amorphous and crystalline forms of candesartan cilexetil using column chromatography
US20100240891A1 (en) 2007-09-28 2010-09-23 Toyama Chemical Co., Ltd. Drug containing benzophenone derivative or its salt
CN100580026C (zh) * 2007-11-01 2010-01-13 重庆大学 通过醚键连接的含二苯甲酮的对硝基-二苯乙烯染料及合成与应用
WO2009069643A1 (ja) * 2007-11-27 2009-06-04 Toyama Chemical Co., Ltd. ３－｛５－［４－（シクロペンチルオキシ）－２－ヒドロキシベンゾイル］－２－［（３－ヒドロキシ－１，２－ベンズイソオキサゾール－６－イル）メトキシ］フェニル｝プロピオン酸またはその塩を含有する固体分散体またはその組成物
CN101225241B (zh) * 2007-12-17 2010-05-26 重庆大学 非共轭型的含二苯甲酮对硝基二苯乙烯染料及其合成与应用
CN100580027C (zh) * 2007-12-17 2010-01-13 重庆大学 通过醚键连接的含二苯甲酮的对硝基偶氮苯染料及其合成与应用
US8067929B2 (en) * 2008-03-03 2011-11-29 Intersil Americas, Inc. High-side sensing of zero inductor current for step down DC-DC converter
DK2258361T3 (da) * 2008-03-27 2014-10-27 Toyama Chemical Co Ltd ANVENDELSE AF ET BENZOPHENONDERIVAT ELLER ET SALT DERAF I KOMBINATION MED EN TNFalfa-INHIBITOR OG FARMACEUTISK SAMMENSÆTNING INDEHOLDENDE DERIVATET ELLER SALTET DERAF OG INHIBITOREN
WO2009131098A1 (ja) * 2008-04-22 2009-10-29 富山化学工業株式会社 ベンゾフェノン誘導体またはその塩および免疫抑制剤を組み合わせて使用する方法ならびにこれらを含有する医薬組成物
US20110112158A1 (en) * 2009-11-11 2011-05-12 David Robert Bolin Benzisoxazole analogs as glycogen synthase activators
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
CA2800971A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CN103183647B (zh) * 2011-12-28 2017-06-09 天津市国际生物医药联合研究院有限公司 3‑{[2‑[3‑氧‑(1,2‑苯并异噻唑‑6‑基)甲氧基‑5‑(2‑羟基‑4‑环戊氧基苯甲酰基)]苯基}丙酸的制备方法
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
WO2014157623A1 (ja) * 2013-03-29 2014-10-02 富山化学工業株式会社 ベンゾフェノン誘導体またはその塩を含有する肺高血圧症治療薬
CN106565529A (zh) * 2015-10-13 2017-04-19 天津国际生物医药联合研究院 3-(2-((3-氨基甲酰基-4-羟基)苄氧基)-5-(取代苯甲酰)苯丙酸衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320490C (en) 1987-01-12 1993-07-20 Darrel M. Gapinski Anti-inflammatory agents
US5273999A (en) * 1991-09-10 1993-12-28 Hoffmann-La Roche Inc. Carboxylic acid leukotriene B4 antagonists
EP1127869A4 (en) * 1998-11-05 2007-05-02 Toyama Chemical Co Ltd NOVEL COMPOUNDS AND THEIR MEDICAL USE
JP4976617B2 (ja) * 2000-03-17 2012-07-18 富山化学工業株式会社 新規なベンゾフェノン誘導体およびその塩

Also Published As

Publication number Publication date
MXPA04004654A (es) 2005-05-17
KR20050044458A (ko) 2005-05-12
JP4554926B2 (ja) 2010-09-29
HUP0402025A3 (en) 2006-01-30
ES2394963T3 (es) 2013-02-07
ZA200403373B (en) 2006-01-25
CN1602291A (zh) 2005-03-30
CA2467261C (en) 2010-10-12
CN1602291B (zh) 2010-05-12
NO329094B1 (no) 2010-08-23
RO123430B1 (ro) 2012-04-30
PL370224A1 (en) 2005-05-16
PL206100B1 (pl) 2010-06-30
CY1113657T1 (el) 2016-06-22
DK1445249T3 (da) 2012-12-17
EP1445249B1 (en) 2012-11-07
US20050113400A1 (en) 2005-05-26
BR0214177A (pt) 2004-09-14
NO20042495L (no) 2004-08-11
WO2003042150A1 (fr) 2003-05-22
JPWO2003042150A1 (ja) 2005-04-07
US7772285B2 (en) 2010-08-10
NZ532810A (en) 2005-03-24
EP1445249A4 (en) 2006-03-08
PT1445249E (pt) 2013-01-16
AU2002349777B2 (en) 2007-12-20
CA2467261A1 (en) 2003-05-22
IL161736A0 (en) 2005-11-20
IL161736A (en) 2008-06-05
KR100947253B1 (ko) 2010-03-11
EP1445249A1 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
HUP0402025A2 (hu) Új benzofenon származékok és sóik és alkalmazásuk
ATE386028T1 (de) Zyklohexylsulfone als gamma-sekretase-inhibitoren
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
DE60112055D1 (de) Inhibitoren von gamma-secretase
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
NO20070606L (no) Inhibitorer av IAP
ATE401314T1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
AR026915A1 (es) Novedosas pirazolcarboxamidas y pirazoltioamidas como fungicidas
CY1108714T1 (el) Ανταγωνιστες υποδοχεα cgrp
ATE450533T1 (de) Carboxamidderivate
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
AP1541A (en) New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
PL1685142T3 (pl) Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
NO20054340L (no) Nye sammenkoplede heterocykler og deres anvendelse
SE0301446D0 (sv) New Compounds
TW200512201A (en) New heterocyclic amides
TW200420545A (en) 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
TNSN06142A1 (en) Cycloalkyl derivatives of 3-hydroxy-4-pyridinones
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
HUP0204501A2 (hu) Gyűrűs vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására és alkalmazásuk
DE69919478D1 (de) 7-Aminopyrido(2,3-d)-pyrimidine Derivate zur Behandlung von Bronchialasthma

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: TOYAMA CHEMICAL CO. LTD., JP

Free format text: FORMER OWNER(S): TOYAMA CHEMICAL CO., LTD., JP; HIRONO, SHUICHI, JP; SHIOZAWA, SHUNICHI, JP

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished